Report highlights The event described the company's release of its annual report on March 30. In 2015, we achieved revenue of 271 million yuan, up 20.37% year on year, net profit of 75.1531 million yuan, up 50.73% year on year, after deducting non-net profit of 73.52 million yuan, up 51.98% year on year and EPS 0.36 yuan. At the same time, it is proposed to distribute a cash dividend of 1 yuan (tax included) for every 10 shares, and 10 additional shares will be transferred for every 10 shares. At the same time, the first quarter results forecast was released: Net profit returned to mother for the first quarter was 9.8683 million yuan - 10.07 million yuan, an increase of 160% to 190% over the previous year. Incident review performance has grown rapidly, and Shixuan has surpassed its performance. The traditional power transmission and distribution related business achieved revenue of 201 million yuan, a year-on-year decrease of 1.99%, and gross margin increased sharply by 7.2 percentage points to 60.77% year-on-year; the healthcare business achieved revenue of 69.8929 million yuan, a sharp increase of 250.38% over the previous year. Shixuan Technology achieved net profit of 52.5517 million yuan for the whole year, a sharp increase of 59.98% over the previous year, exceeding the promised performance (46.875 million yuan). During the reporting period, it only consolidated its fourth quarter results of 22.9745 million yuan. The traditional business is steady, and the medical sector is advancing at an accelerated pace. With the increase in investment in the national distribution network, the company's traditional business continued to grow rapidly since the third quarter. The parent company, which specializes in traditional business, achieved a net profit of 512.321 million yuan throughout the year, and signed a total contract amount of 339 million yuan throughout the year. We expect that abundant orders will help continue the growth trend. In the medical sector, Daqian's biological diagnostic reagent product line is further complete. It has a total of 90 medical device registration certificates, and has the ability to provide the most complete laboratory solutions for various medical institutions. Its business covers 26 provinces, cities, and autonomous regions across the country. Strong R&D capabilities and extensive customer resources support its rapid growth. Daqian achieved a net profit of 5.7019 million yuan throughout the year, and is still in an explosive period. Exxon Biotech completed the development of its own products and signed an exclusive distribution agreement with DIAGNOSTICA STAGO in 13 provinces. It achieved annual revenue of 7.0899 million yuan, a sharp increase of 765.57% over the previous year, and is expected to continue to explode and achieve break-even in 2016. At the same time, the total number of users of Shixuan Technology's medical information technology products has reached more than 2,000, and its business has spread across 23 provinces across the country, continuing the high growth trend. We believe that as the company's medical sector accelerates, the synergy of its strong medical informatization resources, rich in-house IVD products, and exclusive distribution of high-quality varieties will quickly be reflected. Overall, the company's medical sector pattern has now taken shape and will become the core driving force for the company's growth in the future. The dividends of the hierarchical diagnosis and treatment policy are expected to be implemented. In September 2015, the State Council focused on deploying a plan to establish a hierarchical diagnosis and treatment system, and all provinces across the country introduced implementation policies one after another. In 2017, the hierarchical diagnosis and treatment system in each region will be basically completed. We believe that hierarchical diagnosis and treatment will become the next frontier in the Internet medical field, and Shixuan is expected to fully benefit from its high-quality health information platform resources and medical informatization capabilities, and is expected to accelerate growth with a new model. Set up an investment company to accelerate the layout of a new starting point. The company invested 50 million yuan to establish the Zhongyuanhui Industrial Investment Company, which is expected to use a professional team to expand the company's business areas and investment channels. The company has carried out a series of layouts around the medical industry in recent years, and is progressing smoothly in terms of strategy and implementation. We believe that the establishment of the company's investment company or ushered in a new starting point in related business layout, and the development prospects are worth looking forward to. The medical ecosystem is advancing at an accelerated pace and maintaining a “buy” rating. The company has excellent quality, stable traditional business, and strong medical business synergy. Since transforming the medical business, it has grown rapidly and has great potential for the future. EPS is expected to be 0.5 yuan, 0.75 yuan, and 0.92 yuan in 2016, 2017, and 2018. We are optimistic about the company's determined promotion of the medical sector business and maintain a “buy” rating. Risk Warning: Business is not progressing as fast as expected